The central obstacle, the authors explain, is heterogeneity. Oesophageal adenocarcinoma is driven in large part by chromosomal instability, a process that generates large-scale genomic chaos rather than the tidy, single-gene mutations seen in some other cancers. This instability produces profound differences not only between patients but also between different regions of the same tumour and between the primary tumour and its metastases. Two cells sitting centimetres apart within one patient’s oesophagus may carry different copy-number landscapes, different mutational burdens and different vulnerabilities. A therapy that eradicates one subclone may simply clear the way for another, which is why responses to treatment are so variable and why resistance so often emerges. Any model that smooths over this complexity risks giving clinicians a misleading picture of how a real tumour will behave.

Precision oncology promises to match each treatment to the biology of each tumour, but the review makes clear that in oesophageal cancer this promise has been constrained by history. Conventional two-dimensional cell lines—the workhorses of cancer biology for decades—grow quickly, are cheap and are easy to manipulate genetically, yet decades of passaging in plastic have driven them far from the tumours they originally came from. They lack the three-dimensional architecture of real tissue, they have lost most of the stromal and immune cells that surround a tumour in the body, and their genomes often no longer reflect the patient’s disease. They remain useful for dissecting mechanisms, the authors concede, but as avatars of an individual patient they fall short of what translational medicine now demands.

The models that have attracted the most excitement in recent years are patient-derived organoids: miniature, self-organising tumour fragments grown from fresh biopsy or surgical tissue in a supportive extracellular matrix. Because they are established directly from a patient and expanded for only a limited number of passages, organoids preserve much of the genotype and phenotype of the parent tumour, including the copy-number aberrations that dominate oesophageal adenocarcinoma. Crucially, they can be grown in multi-well formats, meaning dozens of drugs and drug combinations can be tested against a patient’s own tumour cells within days to weeks—a time horizon that can genuinely inform clinical decision-making. Studies across multiple cancer types have shown that organoid drug responses can predict patient responses with encouraging accuracy, and the review highlights their potential as functional biomarkers for treatment selection in oesophageal cancer specifically.

Yet organoids have an inherent limitation: they usually contain only the epithelial cancer cells. The tumour microenvironment—the fibroblasts, immune cells, blood vessels and signalling molecules that bathe a tumour in vivo—is largely absent, and it is this microenvironment that determines whether immunotherapies work. To close that gap, researchers are developing co-culture systems that introduce cancer-associated fibroblasts or immune cells into organoid cultures, and the review singles out immune-augmented organoid platforms as one of the most promising frontiers. By embedding tumour organoids with autologous immune cells, laboratories can begin to run functional immunology readouts: measuring whether a patient’s own T cells recognise their tumour, whether immune checkpoint blockade reinvigorates an anti-tumour response, and whether resistance mechanisms are already at play. Such systems offer a glimpse of personalised immunotherapy testing—something barely imaginable a decade ago.

At the other end of the biological fidelity spectrum sit patient-derived xenografts, or PDX models, in which fragments of a patient’s tumour are implanted into immunodeficient mice. These models retain the three-dimensional architecture, stromal interactions and evolutionary dynamics of the original tumour, and because they grow inside a living organism they capture whole-body pharmacology—how a drug is absorbed, distributed, metabolised and cleared—that no dish can replicate. Orthotopic variants, implanted directly into the oesophagus, add anatomical realism, while humanised PDX mice, engrafted with a human immune system, allow immunotherapies to be studied in a living setting. The trade-off, the authors stress, is throughput and time: establishing a PDX line takes months, success rates vary, and the cost and animal requirements limit how many patients can be modelled at scale. PDX models therefore serve best as deep characterisation platforms and for studying evolutionary and pharmacological questions rather than as rapid diagnostic tools.

Between the dish and the mouse lies a class of models that the review treats with particular attention: ex vivo organotypic tissue slice platforms and histocultures. Rather than dissociating a tumour or passaging it, these approaches take fresh slices of the actual surgical specimen—preserving the full cellular ecosystem of cancer cells, stroma, vasculature and immune infiltrate—and keep them alive in culture for days to a few weeks. Because nothing is disrupted, these slices offer what may be the highest fidelity to the parent tumour of any platform, and their short turnaround makes them attractive for clinically aligned endpoints such as predicting a patient’s response to neoadjuvant chemotherapy or radiotherapy before treatment begins. The limitations are equally practical: slice viability is finite, oxygen and nutrient penetration constrain slice thickness, and standardisation across laboratories remains immature. Nonetheless, the authors argue that organotypic cultures, especially when paired with immune readouts, occupy a unique translational niche for short-horizon therapeutic testing.

The review then turns to a rapidly accelerating dimension of cancer modelling that involves no cells at all: computation. In silico inference pipelines now integrate whole-genome sequencing, transcriptomics, epigenetics and imaging data to infer tumour evolutionary history, predict vulnerabilities and stratify patients, while computational histopathology—increasingly powered by deep learning applied to routine pathology slides—can extract prognostic and predictive information at a scale no experimental model can match. Digital approaches offer unlimited scalability and near-instant results, and they can integrate multi-omic and imaging information that fragmented experimental systems capture only in part. But the authors are emphatic about a caveat: algorithms trained on retrospective data are only as good as their validation, and rigorous benchmarking against real patient outcomes and against experimental models is essential before computational predictions can safely guide therapy. The most credible future, they suggest, is not a single winning platform but a triangulation in which genomic inference, organoid and slice-based drug testing, and selective PDX experiments corroborate one another.

What emerges from the survey is a portfolio philosophy. No single model satisfies all the translationally relevant criteria the authors apply—fidelity to the parent tumour, representation of stromal and immune compartments, scalability, time-to-result and suitability for clinically aligned endpoints such as response prediction and resistance evolution. Organoids win on speed and scalability; organotypic slices win on microenvironmental fidelity and clinical turnaround; PDX models win on organism-level pharmacology and evolutionary context; and computational pipelines win on throughput and data integration. Used intelligently and in combination, these platforms could finally give oncologists what oesophageal adenocarcinoma has long denied them: a way to test, in advance and in the laboratory, whether a given therapy will work for a given patient, and to watch resistance evolve before it happens in the clinic.

The stakes could hardly be higher. As immune checkpoint inhibitors reshape frontline treatment of gastro-oesophageal cancers and a growing arsenal of targeted agents waits in the wings, the absence of reliable predictive biomarkers means many patients endure toxic therapies from which they derive little benefit, while potentially effective options go untried. The Birmingham team, whose work was supported by Cancer Research UK and the Sir Arthur Thomson Charitable Trust, frames its review as both a critical appraisal and a call to action: the model-building tools now exist, but the field must invest in head-to-head comparisons, standardisation and prospective validation against patient outcomes. If that work succeeds, the era of treating oesophageal adenocarcinoma by trial and error could give way to one in which a patient’s tumour is first grown, challenged and computationally interrogated in the laboratory—so that the first real experiment happens where it matters most, in the clinic, with the odds stacked in the patient’s favour.

Subject of Research: Preclinical and computational modelling of oesophageal adenocarcinoma for precision oncology and immunotherapy

Article Title: Modelling oesophageal adenocarcinoma for precision oncology and immunotherapy

Article References: Anwar, R., Rose, E., Swirsky, F., Kunene, V., & Contino, G. (2026). Modelling oesophageal adenocarcinoma for precision oncology and immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04447-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04447-3

Keywords: oesophageal adenocarcinoma, tumour heterogeneity, patient-derived organoids, patient-derived xenografts, immunotherapy, precision oncology, drug sensitivity, tumour microenvironment, computational histopathology, chromosomal instability, personalised medicine, cancer models

The review arrives at a moment of growing frustration in breast cancer management. Although surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted agents have dramatically improved outcomes for many patients, a substantial proportion still experience recurrence and progression. One reason is that breast cancer is not a single disease. Its molecular subtypes—luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC)—each carry distinct biological behaviors, respond differently to the same drugs, and recur at different rates. Clinicians have long sought biomarkers that can be measured after diagnosis to guide treatment decisions in real time, and metabolites are emerging as unusually informative candidates.

The logic behind metabolomics is rooted in a fundamental feature of cancer biology. Tumor cells rewire their metabolic machinery to sustain energy production, maintain redox balance, and fuel relentless biosynthesis even under the hostile conditions of hypoxia and nutrient scarcity that characterize the tumor microenvironment. Because metabolites sit at the very end of the chain linking genes to proteins to cellular function, they offer a dynamic and sensitive readout of what a tumor is actually doing—often a more faithful snapshot of phenotype than genomic or proteomic data alone. Metabolites also participate directly in signaling, immune evasion, and epigenetic modification, meaning they are not merely passive byproducts but active participants in malignant progression.

To build their evidence map, the researchers conducted a systematic PubMed search covering studies published between 2006 and 2025, screening 445 initial hits down to 53 clinical studies involving human biological samples. Of these, 36 addressed metabolomics for monitoring therapeutic response, 9 focused on prognostic markers, and 8 examined signatures of disease progression. The studies drew on a variety of biological materials—serum most commonly, followed by plasma, tumor tissue, urine, and feces—and employed a range of analytical platforms. Liquid chromatography-mass spectrometry (LC-MS) dominated the field, with nuclear magnetic resonance (NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) as important alternatives. Most studies (41) used untargeted approaches that survey the metabolome broadly, while 7 used targeted methods and 5 combined both strategies.

One of the review’s most striking findings is how rapidly cancer treatments themselves reshape the metabolic landscape. Within the first 24 hours of paclitaxel administration, patients show significant changes in plasma concentrations of 2-hydroxybutyrate, 3-hydroxybutyrate, pyruvate, and several amino acids involved in the TCA cycle and glycolysis. Longer courses of chemotherapy perturb sphingolipid metabolism and the biosynthesis of phenylalanine, tyrosine, and tryptophan, while adjuvant regimens alter tyrosine metabolism, lysine degradation, and branched-chain amino acid synthesis. Targeted therapies leave their own fingerprints: anti-HER2 treatment elevates plasma methionine in metastatic patients, and trastuzumab increases pantothenic acid, taurine, and L-histidine in early breast cancer. Even surgery and radiotherapy produce detectable shifts. Post-surgical plasma shows rises in sucrose—possibly reflecting prolonged physiological stress—and dodecanoic acid, an apoptosis-inducing fatty acid suggesting metabolic recovery after tumor removal. Remarkably, radiotherapy shifted several serum metabolites, including leucine, isoleucine, and lactate, toward levels observed in healthy individuals, hinting at partial metabolic normalization.

Beyond documenting these shifts, the review highlights metabolomics’ real clinical promise: predicting who will respond to neoadjuvant chemotherapy (NAC), the treatment given before surgery to shrink tumors. Achieving a pathological complete response (pCR) after NAC strongly predicts better survival, so knowing in advance who will benefit is invaluable. Here, the studies reveal subtype-specific patterns. In HER2-positive breast cancer, two independent studies found that elevated pre-treatment serum spermidine predicted good response to NAC combined with anti-HER2 agents. This polyamine likely works through antitumor immunity—intratumoral spermidine accumulation correlates with activated CD8+ T cells, and high tumor-infiltrating lymphocytes are known to predict better NAC response in this subtype.

In TNBC, the picture is more complex but equally intriguing. Poor responders showed increases in chlorokynurenine, anthranilic acid, and 3-hydroxykynurenine in pre-treatment plasma, along with elevated acetylated polyamines—pointing to altered tryptophan and polyamine metabolism, both deeply intertwined with immune regulation. Another study found that responders had decreased plasma trimethylamine N-oxide (TMAO), a gut microbiota-produced metabolite previously shown to activate endoplasmic reticulum stress kinase PERK, triggering gasdermin E-mediated pyroptosis in tumor cells and enhancing CD8+ T cell-mediated antitumor immunity. Even fecal metabolites have entered the picture: an NMR study of luminal breast cancer found that good NAC responders excreted higher levels of amino acids such as methionine, valine, alanine, and isoleucine—possibly reflecting reduced tumor demand for these building blocks as the cancer shrank. This noninvasive sampling approach also underscores the interplay between gut microbiota and chemotherapy efficacy.

Metabolomics may also forecast the dark side of treatment. The review cataloged studies linking metabolic signatures to chemotherapy-induced peripheral neuropathy, hypersensitivity reactions, cardiometabolic complications, pain, fatigue, and long-term neurologic toxicity. Histidine emerged as a recurring culprit: levels of this essential amino acid predicted the severity of paclitaxel-induced neuropathy and differed between patients who experienced doxorubicin-related hypersensitivity and those who did not. Mechanistically, histidine is converted by histidine decarboxylase into histamine, the classic mediator of allergic responses and an inflammatory neuromodulator. Aromatase inhibitor-related musculoskeletal symptoms—common in postmenopausal patients on long-term endocrine therapy—were associated with upregulated organic acids and downregulated lipid and sphingolipid pathways. Even radiotherapy-induced skin reactions showed a metabolic signature involving 13 markers, including ethanolamine and thymine, with alanine, aspartate, and glutamate metabolism most significantly altered. Such pharmacometabolomics could one day enable early intervention and dose modification before toxicity becomes debilitating.

For disease monitoring, metabolomics offers the tantalizing prospect of catching recurrence before imaging can. Patients with recurrent breast cancer exhibited significantly lower serum levels of formate, histidine, proline, choline, glutamic acid, and other metabolites compared with non-recurrent patients, with branched-chain amino acid metabolism—specifically the degradation of valine, leucine, and isoleucine—showing significant disruption. A multicenter study of preoperative serum in ER-positive early breast cancer identified a metabolite signature that independently predicted recurrence regardless of clinicopathological factors, with recurrent patients showing elevated valine, leucine, isoleucine, choline, phenylalanine, histidine, glycine, tyrosine, and lactate. The involvement of branched-chain amino acids makes biological sense: they fuel the TCA cycle for ATP production, activate mTOR signaling to drive proliferation, and valine specifically promotes cell-cycle progression through translational regulation of cyclin D2. Metabolic signatures also shift across disease stages and metastatic sites. Early-stage disease shows predominant carbohydrate metabolism, stage II features disrupted glycerophospholipid remodeling, and metastatic patients display elevated acetoacetate, ketone bodies, phenylalanine, and glutamate—the latter fueling invasion through glutathione production and the system Xc-antiporter. A 15-metabolite panel predicted brain metastasis with 96.9% accuracy.

Prognostically, the most consistent signal across studies is lactate. Elevated lactate and glycine in tumor tissue, and elevated lactate and pyruvate in serum, correlate with reduced relapse-free survival and overall survival, particularly in ER-positive patients. Lactate is far more than waste: it acidifies the tumor microenvironment to promote invasion, stimulates angiogenesis through hypoxia-related pathways, suppresses cytotoxic T cells and natural killer cells, renders tumors resistant to radiotherapy, and even regulates gene expression through lactylation, a post-translational modification that drives tumor progression. Bile acids tell a contrasting story: glycochenodeoxycholate levels were positively associated with survival and inversely correlated with tumor proliferation scores. In TNBC, elevated plasma diacetylspermine, a spermine catabolite, marked increased metastasis risk and poorer survival.

The authors are candid about the field’s obstacles. Analytical platforms differ in sensitivity and metabolite coverage, sample handling varies widely, chemotherapy regimens are often pooled in ways that obscure drug-specific effects, and definitions of response differ between studies using pCR, residual cancer burden, RECIST criteria, or survival endpoints. Small sample sizes—ranging from 8 to 699 patients—compound the problem, and confounders such as diet, comorbidities, and smoking are often unaddressed. Only a minority of studies performed subtype-specific analyses or integrated metabolomics with other omics layers. The review calls for large, multi-institutional prospective trials with standardized protocols, longitudinal sampling designs, and multi-omics integration.

Still, the trajectory is clear. Metabolomics offers something conventional biomarkers and imaging cannot: the ability to detect early biochemical perturbations that precede visible disease change, from a noninvasive blood sample, repeatedly over time. If the field can achieve the standardization the authors demand, metabolic fingerprints—especially when fused with genomic and transcriptomic data—could transform breast cancer from a disease managed by population averages into one monitored molecule by molecule, patient by patient.

The platform relies on patient-derived organoids, three-dimensional clusters of tumor cells grown in a supportive gel that recapitulate key architectural and molecular features of the original cancer. Organoids have generated enormous enthusiasm in precision oncology because they allow clinicians to screen multiple drugs against a living surrogate of a patient’s tumor before committing that patient to a regimen. Yet the conventional route to building them, which begins with surgically resected or biopsied tissue, carries substantial drawbacks. Tissue acquisition is invasive, often requires a procedure that may not be clinically justified, and yields samples with low tumor cellularity. The resulting cultures can be contaminated with stromal and immune cells that dilute the tumor-specific signal, and establishment rates for pancreatic cancer organoids have historically been frustratingly low.

The Yonsei University team, led by researchers from the Division of Gastroenterology in collaboration with the Departments of Pathology and Hepatobiliary and Pancreatic Surgery at Severance Hospital, took a different route entirely. Rather than solid tissue, they started with malignant effusions, the pleural fluid that accumulates around the lungs and the ascitic fluid that pools in the abdomen of patients with advanced pancreatic ductal adenocarcinoma. These fluids are collected routinely for symptom management through minimally invasive drainage procedures, meaning that the raw material for organoid culture is essentially a clinical byproduct. Because the fluid already contains free-floating tumor cells shed from metastatic deposits, the researchers reasoned that it could serve as a rich, relatively pure starting inoculum.

Their reasoning proved correct. Fluid-derived organoids, or FDOs, established from these effusions grew faster than organoids generated from matched tissue samples, showed a higher establishment success rate, and carried markedly less non-tumor contamination. The comparison was not simply a matter of convenience. The team performed extensive quality control to demonstrate that FDOs faithfully mirror the biology of the parental tumors. Histopathological examination of hematoxylin and eosin stained sections showed that the organoids retained the glandular architecture characteristic of pancreatic ductal adenocarcinoma. Immunostaining for cytokeratin 7, an epithelial marker expressed in pancreatic ductal cells, confirmed ductal origin. Critically, mutation analysis confirmed that the organoids carried the same KRAS driver mutations as the original tumors. Since activating mutations in KRAS, most commonly at codon 12, occur in the vast majority of pancreatic cancers and anchor much of the field’s targeted drug development, this genetic concordance is essential for the model to have any translational value.

To characterize organoid morphology and drug response in fine detail without destructive processing, the researchers turned to holotomography, a label-free imaging technique that uses coherent light to reconstruct three-dimensional refractive index maps of living cells. This allowed quantitative measurement of cellular and organoid morphology and of how the structures changed in response to drug exposure, complementing conventional viability assays.

One of the most clinically significant demonstrations involved MRTX1133, a selective inhibitor of the KRAS G12D mutant protein. KRAS G12D is among the most common KRAS variants in pancreatic cancer, and MRTX1133 has emerged as a preclinical benchmark for direct KRAS targeting in this tumor type. In the study, FDOs harboring the KRAS G12D mutation showed marked sensitivity to the inhibitor, confirming that the fluid-derived platform can reproduce the drug-response behavior expected of a genetically defined tumor. The result establishes a proof of concept that FDOs can serve as a rapid and scalable test bed for emerging targeted agents, potentially shortening the path from genetic diagnosis to an individualized treatment decision.

The second major contribution of the study goes beyond the platform itself and into the molecular roots of chemotherapy failure. Gemcitabine, a nucleoside analog that has anchored pancreatic cancer chemotherapy for years, frequently stops working as tumors evolve resistance. To understand why, the team performed transcriptomic profiling, comparing gene expression in FDOs that responded to chemotherapy with expression in those that did not. Gene set enrichment and differential expression analysis converged on three genes that were consistently upregulated in the resistant cultures: CEMIP, which encodes cell migration inducing hyaluronidase 1; CALB2, which encodes calbindin 2, also known as the heart and neural crest derivatives expressed protein; and LY6D, a member of the lymphocyte antigen 6 family of glycosylphosphatidylinositol-anchored cell surface proteins.

Expression alone does not prove causation, so the researchers moved to functional validation. When they manipulated the activity of these genes in pancreatic cancer cell lines, the results were unambiguous: elevated CEMIP, CALB2, and LY6D suppressed apoptosis, the programmed cell death pathway that gemcitabine is designed to trigger, and thereby conferred resistance to the drug. CEMIP in particular has been previously implicated in hyaluronic acid metabolism and epithelial-mesenchymal transition, processes that pancreatic tumors exploit to remodel their microenvironment and escape cytotoxic stress. The new findings place all three genes squarely in the mechanistic chain linking cellular stress to survival.

The clinical implications of the three-gene signature were reinforced by outcome data. In analyses of patient cohorts, high expression of the CEMIP, CALB2, and LY6D signature correlated with worse progression-free survival and worse overall survival, indicating that the same genes that protect organoids from gemcitabine in a dish are associated with poorer outcomes in patients. This dual role, as both a mechanistic driver and a prognostic marker, is what gives the finding its translational weight. A test measuring the three-gene signature could in principle identify patients unlikely to benefit from standard chemotherapy, steering them toward alternative regimens or clinical trials of targeted and resistance-overcoming strategies. The genes themselves also represent candidate therapeutic targets, since interfering with their activity might restore sensitivity to apoptosis-inducing drugs.

The work also carries broader implications for how organoid models are built across oncology. Effusions are not unique to pancreatic cancer; malignant pleural and peritoneal effusions arise in ovarian, gastric, lung, and breast cancers, among others. A methodology that converts a routine drainage procedure into a high-fidelity drug-screening platform within days rather than weeks could be adapted widely, particularly for patients with advanced disease for whom tissue biopsy is impractical or unsafe. The scalability of the approach addresses one of the persistent bottlenecks of precision oncology: the sheer logistics of generating a personalized model quickly enough for it to influence a treatment decision made under time pressure.

The study was conducted under ethical approval from the Institutional Review Board of Yonsei University with written informed consent from all patients, and it was supported by grants from the National Research Foundation of Korea and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute. The research article was published as an accepted, citable open-access version carrying a permanent digital object identifier, with the final version of record to follow.

Taken together, the findings advance pancreatic cancer research on two fronts simultaneously. They provide a minimally invasive, rapid, and genetically faithful organoid platform derived from malignant effusions, validated against a state-of-the-art KRAS targeted inhibitor. And they expose a concrete molecular mechanism of chemotherapy resistance, distilled into a three-gene signature with demonstrated prognostic power. For a disease in which treatment options remain scarce and clinical timelines are unforgiving, tools that accelerate both drug selection and biomarker discovery are welcome indeed. The next steps, which the researchers and the field more broadly will be watching closely, involve prospective validation of the gene signature in larger patient cohorts and exploration of whether targeting CEMIP, CALB2, or LY6D can resensitize resistant tumors to gemcitabine and other cytotoxic agents.

Lung cancer remains among the world’s most frequently diagnosed and deadly cancers. Although screening programs and targeted therapies have improved outcomes for some patients, major challenges persist. Early-stage disease can be difficult to distinguish from benign abnormalities, tumors can vary dramatically between patients, and the same tumor may evolve during treatment. Conventional clinical workflows often depend heavily on expert interpretation and incomplete snapshots of disease biology. A scan may reveal the shape of a lesion but not fully explain its molecular behavior; a biopsy may identify cancer cells but miss important differences between regions of the tumor; and a blood test may capture circulating signals that are invisible in tissue. Machine learning offers a way to combine these partial views and identify patterns that may be too subtle, multidimensional, or time-dependent for unaided human analysis.

The review was prepared by researchers from Shanghai Jiao Tong University, Qilu Hospital of Shandong University, Chongqing Medical University, and related institutions. The team organizes the field around a simple but powerful chain: data characteristics determine model selection, model performance determines the reliability of predictions, and reliable predictions must ultimately demonstrate clinical value. Five major data sources form the foundation of this framework. Medical imaging contributes information about tumor size, shape, density, texture, location, and changes over time. Multi-omics data—including genomics, transcriptomics, proteomics, and metabolomics—describe the molecular programs associated with tumor development and treatment response. Liquid biopsy can provide minimally invasive signals from circulating tumor DNA, RNA, proteins, or cells. Digital pathology captures cellular architecture at microscopic resolution, while clinical records provide demographic, physiological, treatment, and outcome information.

Each data type presents a different computational challenge. Imaging data are often high-dimensional and spatially structured, making convolutional neural networks and other deep-learning architectures useful for detecting features across pixels or three-dimensional scans. Digital pathology images can contain billions of pixels, requiring systems that divide slides into smaller regions before learning how local cellular patterns relate to a patient’s diagnosis or prognosis. Omics datasets, by contrast, may contain thousands of molecular variables but relatively few patient samples, creating a high risk of overfitting. Traditional machine-learning methods, feature selection, regularization, and dimensionality-reduction techniques can be valuable in such settings because they constrain the model and make its predictions more stable. Clinical data may include missing values, inconsistent terminology, and irregular time points, requiring specialized preprocessing and models capable of handling longitudinal information.

The article compares several generations of machine-learning approaches. Traditional methods such as logistic regression, support-vector machines, random forests, and gradient-boosting algorithms can perform well when datasets are moderate in size and features have been carefully defined. They are often easier to validate and interpret than more complex systems. Deep learning can learn representations directly from raw images, pathology slides, or other unstructured data, reducing the need for manual feature engineering. However, deep models generally require large, diverse, and consistently labeled datasets. Multimodal fusion methods attempt to combine information from different sources, either by integrating features early in the computational pipeline, merging model outputs at a later stage, or using architectures that learn relationships between modalities. These approaches can capture complementary signals, but they also face the problem of missing or poorly aligned data.

Foundation models represent another emerging direction. Trained on very large datasets, these models can learn general biological or visual representations and then be adapted to particular lung cancer tasks with less task-specific data. In principle, a foundation model trained on broad medical images or pathology material could be fine-tuned for nodule classification, tumor segmentation, subtype recognition, or treatment-response prediction. Yet the review emphasizes that scale alone does not guarantee clinical reliability. Training data may reflect one hospital, one scanner type, one population, or one style of clinical documentation. A model can therefore appear highly accurate in development while failing when transferred to a different institution. External validation, calibration, transparent reporting, and continuous monitoring are essential before such systems can influence patient care.

In early detection and diagnosis, multi-source machine learning could help clinicians distinguish malignant nodules from benign findings, prioritize patients for further testing, and identify cancers that might otherwise be overlooked. Imaging models can analyze subtle radiological patterns, including texture and spatial relationships that are difficult to describe using conventional measurements. When imaging is combined with clinical information, smoking history, laboratory results, or molecular signals from blood, the resulting prediction may be more informative than any single source alone. Similar strategies could support pathological diagnosis by linking tissue morphology with molecular subtypes and clinical outcomes. The aim is not simply to automate a radiologist’s or pathologist’s work, but to provide additional evidence, reduce variation, and help specialists focus attention on ambiguous or high-risk cases.

Treatment selection is another major area of opportunity. Lung cancer includes biologically distinct diseases that can respond very differently to surgery, chemotherapy, radiotherapy, targeted drugs, or immunotherapy. Machine-learning models can search for associations between molecular alterations, imaging features, pathological characteristics, treatment histories, and outcomes. These analyses may help estimate the probability that a patient will benefit from a particular therapy or develop resistance. Repeated measurements also make it possible to track disease dynamically. Changes in circulating tumor DNA, radiological appearance, or laboratory indicators could be analyzed over time to detect treatment response earlier than traditional assessments. Such systems could support adaptive treatment strategies, although the review stresses that predictions must be tested in prospective clinical studies rather than accepted solely on the basis of retrospective datasets.

Prognosis is similarly moving from a single end-of-treatment estimate toward continuous risk assessment. By integrating tumor biology, disease stage, treatment response, comorbidities, and follow-up information, machine-learning systems may identify patients at different risks of recurrence, progression, or treatment-related complications. This could allow surveillance schedules and supportive care to be tailored more precisely. However, the review identifies several barriers between promising algorithms and routine clinical use. Data standards remain inconsistent across hospitals; imaging protocols and pathology procedures vary; omics measurements can be expensive and technically heterogeneous; and patient records frequently contain missing or biased information. Multimodal models may also become less reliable when one data source is unavailable. In addition, clinicians and patients need to understand why a model produces a recommendation, especially when that recommendation affects an invasive procedure or life-changing therapy.

The researchers propose that future progress should focus on standardized data collection, adaptive fusion of complementary modalities, interpretable artificial intelligence, and prospective validation in real clinical environments. Interpretability does not necessarily mean reducing a complex model to a simple formula. It may involve showing which image regions influenced a prediction, identifying the molecular features associated with risk, quantifying uncertainty, or explaining how a patient’s current result differs from comparable cases. Fairness and privacy will also be central as hospitals connect large datasets and develop shared learning systems. Techniques such as federated learning could allow institutions to train models without transferring raw patient records, while robust governance frameworks could define how algorithms are audited, updated, and held accountable. The long-term vision presented in the review is a closed-loop lung cancer system in which early screening, diagnosis, personalized treatment, and prognosis are connected through continuously updated evidence. If that vision can be translated safely into practice, machine learning may help shift lung cancer management from experience-driven decisions toward precise, dynamic, and patient-specific care.

Subject of Research: Multi-source data-driven machine learning applications in lung cancer diagnosis, treatment, and prognosis.

Article Title: “Multi-source data-driven machine learning for lung cancer: diagnosis, treatment, and prognosis”

News Publication Date: 29 June 2026

Web References: https://doi.org/10.67704/ioe.2026.260006

References: Original review published in Intelligent Opto-Electronics, DOI: 10.67704/ioe.2026.260006.

Image Credits: Editorial Office of Opto-Electronic Journals Group.

Keywords: Lung cancer, machine learning, artificial intelligence, multimodal data, medical imaging, multi-omics, liquid biopsy, digital pathology, precision medicine, prognosis.

This year’s selections were chosen by an advisory board drawn from pharma and biotech leadership, venture investors, and life sciences executives. Their evaluations focused on the projects’ potential to move beyond proof-of-concept and toward assay development, therapeutic engineering, and technology readiness for broader adoption.

One funded effort will produce an assay intended to guide pancreatic cancer treatment decisions by distinguishing between tumor subtypes of ductal adenocarcinoma. The goal is to align therapeutic selection with underlying biology, improving the odds that targeted strategies match the patient’s disease profile.

In immunotherapy, a separate project seeks to improve CAR-T cell effectiveness by boosting function after the initial infusion. By addressing mechanisms that contribute to relapse in blood cancers, the approach targets durability—an ongoing challenge in engineered cell therapies.

Fred Hutch also funded an antibody-based strategy against herpes simplex virus. The work focuses on enabling long-term suppression in individuals with recurrent infection, with a therapeutic design intended to extend antiviral control rather than provide only short-lived clearance.

Beyond infectious disease and oncology strategies, one award supports a concept for stopping acute myeloid leukemia development by eliminating pre-leukemic cells before they progress into aggressive disease. The approach emphasizes intervention at the earliest detectable pathological stage.

Additional projects expand translational capability through gene and cell-systems targeting. Researchers will explore DLK1 pathway inhibition to affect neuroblastoma engraftment, while another team uses AI-designed miniproteins and peptides to disrupt cancer-specific mechanisms tied to chromosome segregation and tumor cell growth.

Finally, an assay-focused study will identify naturally occurring autoantibodies in patients whose cancers respond to checkpoint inhibitors. The aim is to reveal immune signatures that could inform new therapeutic hypotheses and patient stratification beyond current biomarkers.

The Evergreen Fund, launched in 2016, has supported roughly $8.6 million across 73 projects spanning cancer, infectious diseases, and immunotherapy. Fred Hutch notes that investigators and the institution may benefit if any supported discoveries become commercially viable.

Subject of Research: Translational cancer and immunology research; infectious disease therapeutics
News Publication Date: July 14, 2026
Web References: https://www.fredhutch.org/en/investors/business-development.html
Keywords: Fred Hutch, Evergreen Fund, translational research, CAR-T, pancreatic cancer, herpes simplex virus, acute myeloid leukemia, antibody therapy, AI-designed therapeutics, checkpoint inhibitors, biomarkers

Chemotherapy, while a cornerstone of cancer treatment, carries a host of adverse effects, from fatigue and nausea to more severe complications like immunosuppression and organ toxicity. For patients with early-stage ER+HER2- breast cancer, the decision to undergo chemotherapy currently hinges on genomic risk scores that stratify patients into low, intermediate, or high risk of recurrence. However, the majority of patients fall into an ambiguous intermediate risk category, often leading clinicians to recommend chemotherapy as a precaution despite uncertain benefits. This practice raises critical concerns about overtreatment and underscores the urgent need for tools that can more precisely forecast which patients will genuinely benefit from chemotherapy.

The research team employed cutting-edge AI-driven analysis to decode the tumor microenvironment, specifically focusing on the density of cytotoxic CD8+ T-cells infiltrating the stromal regions adjacent to the tumor. By examining tissue samples from a randomized clinical trial in Ireland, comparing outcomes of hormone-blocking therapy alone versus hormone-blocking combined with chemotherapy in patients with intermediate genomic risk, the team uncovered a compelling prognostic marker. High densities of these cancer-targeting immune cells correlated strongly with poorer responses to chemotherapy. This counterintuitive finding challenges conventional paradigms and highlights the nuanced interplay between the immune system and cancer therapeutics.

This innovative approach harnesses digital pathology and machine learning algorithms to quantify immune cell presence in tumor-adjacent tissue—a task that surpasses the capabilities of traditional histopathological evaluation. Unlike current genomic assays that primarily analyze tumor cells themselves, this method incorporates the spatial context of immune infiltration, providing a more holistic view of tumor biology. Because it utilizes standard formalin-fixed, paraffin-embedded tissue samples routinely collected during diagnosis, this AI-based technique promises scalability and seamless integration into existing clinical workflows, paving the way for widespread adoption.

Professor Darran O’Connor, who led the research at the RCSI School of Pharmacy and Biomolecular Sciences, emphasizes the clinical significance of these results. He notes that patients with intermediate genomic risk face difficult treatment decisions, often defaulting to chemotherapy out of caution. By introducing immune profiling into the decision-making process, clinicians can better identify those who are unlikely to benefit from chemotherapy, thereby reducing unnecessary exposure to treatment-related toxicity and improving patients’ quality of life. This precision not only enhances patient care but also optimizes healthcare resources.

The study’s findings delineate a clear stratification model: patients with a high stromal density of cytotoxic T-cells exhibited reduced benefit from chemotherapy, suggesting that these immune cells might mediate resistance mechanisms or reflect a tumor microenvironment less amenable to such treatment. This insight opens new avenues for personalized oncology, where immune contexture could guide therapeutic choices. Furthermore, the integration of AI for immune cell quantification represents a leap forward in biomarker discovery and utilization, marrying computational prowess with clinical oncology.

Dr. Zak Kinsella, the study’s first author, highlights the remarkable predictive power of cytotoxic T-cell density in forecasting treatment response. His postdoctoral work at RCSI demonstrated that the AI-enabled analysis could extract nuanced prognostic information that escapes conventional methods, underscoring the value of computational pathology in modern cancer research. This development exemplifies the growing symbiosis between AI technologies and biomedical sciences, fostering innovations that transform clinical practice.

Senior author Professor William Gallagher from UCD’s Conway Institute underscores the necessity of further validation to translate these findings into routine clinical use. Large-scale studies will be essential to confirm the reproducibility and robustness of the AI-based immune profiling across diverse populations and treatment settings. Nonetheless, the study marks a pivotal step toward precision medicine in breast cancer, reducing the dilemma of chemotherapy decision-making for patients with intermediate risk profiles.

This research was realized through a multidisciplinary partnership involving RCSI, University College Dublin, Cancer Trials Ireland, Beaumont Hospital, St. Vincent’s University Hospital, and Queen’s University Belfast. Funding support came from Precision Oncology Ireland as part of the Strategic Partnership Programme of Research Ireland, with additional backing from the ARC Hub for HealthTech, co-funded by the Government of Ireland and the European Union’s ERDF Northern & Western Regional Programme 2021-2027. Such collaborative frameworks highlight the importance of integrated efforts in advancing cancer research.

Looking forward, the researchers have jointly filed a patent for their AI-driven immune profiling technology and are actively pursuing commercialization strategies to facilitate its adoption into clinical settings. They envision a future where treatment decisions for early-stage breast cancer are informed by a sophisticated understanding of immune-tumor dynamics, significantly reducing overtreatment and enhancing patient outcomes globally.

This paradigm-shifting study exemplifies the potential of artificial intelligence to revolutionize oncology by providing clinicians with powerful tools to personalize therapy, improve prognostication, and ultimately redefine standards of care. As the research continues to mature through further validation, it heralds a new chapter in breast cancer management—one that balances therapeutic efficacy with patient-centric care, minimizing harm while maximizing benefit.

Subject of Research: Breast Cancer, Immune Profiling, Chemotherapy Response Prediction

Article Title: Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer

News Publication Date: 23 June 2026

Web References: https://doi.org/10.1038/s41467-026-73432-2

Keywords: Breast cancer, Chemotherapy, Tumor microenvironment, Cytotoxic T-cells, AI in oncology, Immune markers, Personalized medicine, ER+HER2- breast cancer, Genomic risk scoring, Digital pathology, Cancer treatment prediction

Colorectal cancer remains one of the most prevalent and deadly malignancies worldwide, with complex treatment decisions influenced by tumor characteristics, patient health status, and therapeutic toxicity profiles. While adjuvant chemotherapy after surgical resection substantially reduces recurrence risk and improves long-term survival for individuals with localized disease, the variability in treatment tolerance and efficacy creates significant clinical challenges. Understanding how BMI—a key indicator of nutritional status and metabolic health—modulates these outcomes has therefore been a pressing research question with profound clinical relevance.

The OCTOPUS meta-analysis uniquely aggregates comprehensive individual-level data from numerous clinical trials involving thousands of patients with non-metastatic colorectal cancer receiving adjuvant chemotherapy. By harmonizing and analyzing this rich dataset, the researchers have achieved unparalleled statistical power and granularity, enabling them to dissect nuanced associations between BMI categories, chemotherapy-induced toxicities, and survival outcomes with remarkable precision.

One of the pivotal revelations of this meta-analysis is the nuanced, non-linear relationship between BMI and chemotherapy toxicity. Far from a simplistic linear prediction, the findings indicate that both low and high BMI values are associated with distinct toxicity profiles. Patients categorized as underweight encountered increased risks of hematological toxicity, including neutropenia and anemia, likely reflecting compromised physiological reserves and impaired drug metabolism. Conversely, individuals classified as obese exhibited heightened vulnerability to non-hematological toxicities such as gastrointestinal disturbances and neuropathy, potentially attributable to altered pharmacokinetics and comorbidity burden.

Beyond toxicity, BMI demonstrated a complex influence on survival metrics post-adjuvant chemotherapy. The analysis showed that overweight patients enjoyed a modest survival advantage compared to normal-weight counterparts, a phenomenon sometimes referred to as the “obesity paradox” in oncology. However, this benefit diminished and reversed in the severe obesity range, underscoring that extreme adiposity does not confer a protective effect and may exacerbate cancer progression and mortality risks. Intriguingly, underweight patients consistently exhibited poorer survival outcomes, highlighting the detrimental impact of malnutrition and cachexia-related metabolic derangements on therapeutic efficacy.

The study’s detailed pharmacological assessments offer mechanistic plausibility for these observations by elucidating how body composition modulates chemotherapy distribution, clearance, and toxicity thresholds. Adjuvant agents such as fluoropyrimidines and oxaliplatin undergo complex biological processing influenced by adipose tissue, lean muscle mass, and systemic inflammation—all of which vary across BMI strata. Consequently, standardized dosing regimens not tailored to body composition might inadvertently lead to suboptimal drug exposure, increased side effects, or compromised anticancer activity.

Importantly, the OCTOPUS findings carry profound translational significance for precision oncology and clinical guidelines. They underscore the necessity of integrating BMI and body composition assessments into routine oncological evaluations to optimize adjuvant chemotherapy dosing, toxicity monitoring, and supportive care strategies. Personalized interventions that consider nutritional status and metabolic health could mitigate treatment-related adverse events, enhance patient adherence, and ultimately improve survival outcomes.

Furthermore, these insights invite a reevaluation of prevailing BMI thresholds in clinical research and practice. Given the heterogeneous effects observed across BMI categories, more nuanced stratifications beyond conventional cutoffs may better capture individual risk profiles and inform therapeutic decision-making. Incorporating advanced imaging and biomarker analyses to delineate fat distribution and muscle mass could further refine risk prediction models and optimize dose individualization in colorectal cancer treatment.

The comprehensive nature of this meta-analysis also sheds light on the broader systemic challenges faced by cancer patients with abnormal BMI. For example, obesity-associated chronic inflammation and insulin resistance may exacerbate tumor-promoting pathways, while malnutrition impairs immune function and recovery potential after chemotherapy. Addressing these multifaceted biological processes requires multidisciplinary collaboration encompassing oncology, nutrition, pharmacology, and rehabilitation medicine.

Looking ahead, the OCTOPUS investigators advocate for prospective clinical trials explicitly designed to evaluate BMI-guided adjuvant chemotherapy protocols and supportive care interventions in colorectal cancer. Such studies are essential to validate causative relationships and to test whether personalized treatment approaches based on body composition metrics can enhance patient outcomes in real-world settings. Parallel research efforts exploring genomic and molecular correlates of chemotherapy response in the context of BMI will also advance the precision medicine paradigm.

In summary, this landmark meta-analysis decisively advances our understanding of how body mass index influences chemotherapy toxicity and survival in non-metastatic colorectal cancer. It challenges the traditional one-size-fits-all model of adjuvant chemotherapy dosing, advocating for individualized treatment strategies informed by a patient’s metabolic and nutritional profile. As the oncology community moves towards increasingly tailored therapies, these findings highlight the critical importance of integrating comprehensive patient-specific data—such as BMI—to optimize cancer care and improve the lives of thousands affected by colorectal malignancies worldwide.

The OCTOPUS study exemplifies the power of pooled individual participant data meta-analyses in oncology, setting a new standard for evidence synthesis that maximizes data utility and clinical applicability. By illuminating complex interdependencies between patient characteristics, treatment toxicity, and survival outcomes, it reinforces the transformative potential of big-data approaches in refining cancer therapy paradigms. Ultimately, these insights pave the way for more precise, equitable, and effective interventions that can transform colorectal cancer survivorship in the coming decades.

This research not only informs clinical oncologists but also impacts healthcare policymakers, patient advocacy groups, and researchers committed to improving cancer treatment equity. Recognizing the role of BMI in modulating chemotherapy effects provides a novel avenue for interventions that can address disparities in treatment tolerance and outcomes across diverse patient populations. It calls for increased emphasis on nutritional support services and metabolic health optimization as integral components of cancer care pathways.

Moreover, the study highlights the urgent need to incorporate patient-centered outcomes such as quality of life and functional status into routine evaluations, especially in patients with non-standard BMI profiles. By balancing toxicity risks and survival benefits, clinicians can tailor adjuvant chemotherapy regimens that align with patient preferences and goals, fostering shared decision-making and holistic care approaches.

In conclusion, the OCTOPUS individual participant data meta-analysis offers a treasure trove of evidence that reshapes how clinicians consider body mass index in the management of non-metastatic colorectal cancer. Its multifaceted findings catalyze new research directions and clinical innovations aimed at personalizing chemotherapy, mitigating toxicity, and extending survival. This landmark work underscores that body composition is far more than a mere number on the scale—it is a vital determinant of cancer treatment success and patient well-being, demanding targeted attention in future oncological practice and research.

Subject of Research: The relationship between body mass index (BMI), chemotherapy toxicity, and survival in patients with non-metastatic colorectal cancer undergoing adjuvant chemotherapy.

Article Title: Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS).

Article References:
Slawinski, C.G.V., Malcomson, L., Barriuso, J. et al. Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS). Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03472-4

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03472-4

Traditionally, the clinical assessment of oligometastatic disease relies on imaging techniques such as X-rays, computed tomography (CT), and magnetic resonance imaging (MRI) to enumerate metastatic lesions. This approach, however, is somewhat rudimentary, as it depends solely on anatomical visualization and may not capture microscopic tumor burden or impending metastatic progression. Dr. Chad Tang, Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, led this pioneering research. He and colleagues aimed to determine whether quantitative measurements of ctDNA—a surrogate of tumor-derived genetic material circulating freely in the bloodstream—could serve as a dynamic biomarker to better stratify patients and optimize therapeutic decisions.

The concept is that tumors continuously shed DNA fragments into the circulation, and by analyzing this ctDNA, clinicians can gain a real-time molecular snapshot of tumor presence and activity. The trial recruited 237 individuals diagnosed with oligometastatic solid tumors, categorized into six subgroups based on tumor histology: pancreatic, breast, kidney, and prostate cancers (with the latter divided into two distinct treatment arms differing in hormonal therapy regimens), along with a heterogeneous group encompassing other cancer types. Eligible participants had between one and five detectable metastatic lesions. Importantly, patients were randomized to receive either standard systemic drug therapy alone or in combination with high-precision radiotherapy targeted specifically to metastatic sites.

Over the course of the study, blood samples were systematically collected at baseline, three months post-treatment initiation, and at points of disease progression. CtDNA was extracted from plasma and analyzed for tumor-specific mutations or genomic alterations, providing a non-invasive window into tumor dynamics. Results revealed a strong correlation between detectable ctDNA at trial onset and a higher risk of continued tumor proliferation and decreased overall survival. This biomarker proved not only prognostic but also predictive, as patients receiving combined radiotherapy and drug therapy exhibited a more rapid and sustained clearance of ctDNA compared to those treated with drugs alone.

This observation underscores the potentially synergistic effect of local metastasis-directed therapy with systemic treatment, suggesting that radiation may contribute to the eradication of tumor clones disseminating DNA into the bloodstream. The presence of residual ctDNA post-therapy emerged as an ominous sign, implicating subclinical disease persistence or the presence of occult metastases beyond imaging sensitivity. By contrast, clearance of ctDNA heralded superior clinical outcomes, which may indicate effective tumor control and remission.

Dr. Alex D. Sherry, one of the presenting researchers from The Mayo Clinic, emphasized the clinical implications: the ability to monitor treatment efficacy in near real-time via a simple blood test presents a paradigm shift from conventional reliance on intermittent imaging. This form of liquid biopsy could swiftly identify patients who are not responding adequately to current regimens, enabling rapid treatment adaptations before overt disease progression occurs. Moreover, it offers the tantalizing possibility of pinpointing individual metastatic lesions that remain resistant or have acquired therapy-induced mutations, potentially guiding selective intensification or modification of local therapies.

Such precision could significantly impact clinical decision-making by refining patient selection for metastasis-directed radiotherapy and systemic regimens, ultimately personalizing therapy and improving survival. ESTRO President Professor Matthias Guckenberger praised the study for its scale and potential clinical impact, noting that the integration of ctDNA assessment could augment standard imaging modalities. He highlighted the value of this non-invasive biomarker in delineating tumor burden and guiding the timing and targeting of radiotherapy interventions.

Technically, the study employed sophisticated ctDNA extraction and next-generation sequencing techniques, allowing for sensitive detection of tumor-specific genetic alterations at minimal allele frequencies. This high sensitivity is crucial for detecting low levels of tumor DNA in early oligometastatic states. The trial’s randomized design and inclusion of multiple cancer histologies lend robustness and generalizability to the findings, supporting broad applicability across various malignancies.

Looking forward, the research team anticipates future clinical trials to evaluate how systemic systemic therapy should be modified when persistent ctDNA signals are detected post-treatment. Such studies could elucidate mechanisms of resistance and inform dynamic adaptive therapy protocols. Furthermore, integrating ctDNA analyses with emerging imaging techniques and radiotherapy planning tools may enable a truly multimodal, biologically-informed treatment paradigm.

In sum, this landmark study propels ctDNA from a promising research tool toward a practical clinical biomarker that can enhance the precision and effectiveness of cancer treatment. By illuminating the molecular underpinnings of metastasis and therapeutic response in a minimally invasive manner, ctDNA analysis heralds a new era in oncology, where personalized, adaptive care can be delivered with unprecedented accuracy and efficacy.

Subject of Research: People

Article Title: Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND Trial

News Publication Date: 16-May-2026

Web References:
10.1200/JCO-25-02856

References:
Presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026); published in the Journal of Clinical Oncology, May 2026.

Keywords: Cancer, Metastasis, Radiation therapy, Tumor cells, Circulating tumour DNA, Oligometastatic cancer, Liquid biopsy, Radiotherapy, Clinical trial, Personalized medicine, Oncology, Tumour DNA

Breast cancer, known for its heterogeneity, often manifests in forms resistant to standard endocrine therapies. This resistance greatly complicates therapeutic regimens for ER+/HER2- patients, who typically rely on hormone modulation to combat tumor growth. Palbociclib, a CDK4/6 inhibitor, alongside anastrozole, an aromatase inhibitor, offers a combined pharmacological attack by arresting cell cycle progression while simultaneously lowering estrogen production. However, clinical outcomes have been inconsistent, underscoring an urgent need to decipher which patients might truly benefit from this drug combination.

The trial conducted by Kong et al. delves deeply into the molecular underpinnings of varying responses, employing advanced biomarker profiling techniques. Patients enrolled in this study underwent neoadjuvant therapy, aiming to shrink tumors before surgery, thereby providing an invaluable window to assess real-time tumor signaling changes. Tissue biopsies coupled with high-throughput sequencing technologies enabled the identification of specific genetic and proteomic signatures correlating with favorable or resistant outcomes to palbociclib plus anastrozole.

Among the most striking revelations was the role of cell cycle regulatory proteins and signaling pathways in mediating drug response. The study highlighted that tumors exhibiting heightened activity in CDK4/6-dependent pathways had a pronounced sensitivity to the treatment, aligning with the expected mechanism of action of palbociclib. Conversely, tumors showing alterations in compensatory pathways, including PI3K/AKT/mTOR axis activation or cyclin E amplification, frequently demonstrated resistance, thus pointing toward potential escape routes exploited by cancer cells.

Moreover, the researchers uncovered nuanced interplay between hormone receptor status and downstream signaling cascades that influenced sensitivity to aromatase inhibition by anastrozole. Their findings suggest that concurrent evaluation of estrogen receptor functionality alongside cell cycle dynamics could serve as a robust predictive framework. This dual biomarker strategy might empower clinicians to tailor neoadjuvant regimens more effectively, sparing patients from ineffective treatments and associated toxicities.

The implications extend beyond mere prediction. By mapping these molecular landscapes, Kong and colleagues open avenues for combination therapies that might overcome intrinsic resistance. For example, integrating PI3K inhibitors or agents targeting alternative cyclins could potentiate response rates, forging a path toward truly personalized oncology. The detailed biomarker profiles could also facilitate dynamic treatment adaptation, where therapeutic strategies evolve in direct response to tumor molecular shifts observed during neoadjuvant intervention.

Crucially, the trial’s design incorporated rigorous clinical endpoints alongside exploratory molecular analyses, ensuring translational relevance. Pathological complete response rates, progression-free survival, and recurrence risks were examined in concert with molecular alterations, thereby linking laboratory discoveries with patient-centric outcomes. This comprehensive approach underlines the study’s potential to transform clinical practice guidelines, moving from generalized protocols toward precision oncology paradigms.

Importantly, the trial highlights the complexity of endocrine resistance, refuting overly simplistic views of this phenomenon. Instead, it positions resistance as a multifactorial and dynamic process, influenced by genetic, epigenetic, and microenvironmental factors. The fine-grained biomarker resolution achieved offers a blueprint for integrating multi-omics data into clinical decision-making, a crucial step in the era of big data and personalized medicine.

Equally impactful is the trial’s demonstration that neoadjuvant palbociclib plus anastrozole, when administered to the right patient subsets, can yield substantial tumor regression without excessive toxicity. This therapeutic window is vital for surgical planning, as tumor size reduction pre-operatively often correlates with better surgical outcomes and potentially organ preservation. By emphasizing biomarkers for patient stratification, the study illuminates pathways to optimize therapeutic efficacy and safety simultaneously.

Technologically, this study leverages cutting-edge genomic and proteomic platforms, alongside sophisticated bioinformatics pipelines, to distill actionable insights from complex datasets. Machine learning models were applied to integrate diverse biomarker data, refining predictive algorithms for treatment responsiveness. This marriage of computational power and biological understanding exemplifies the future direction of oncology research.

The findings also prompt a reevaluation of standard endocrine therapy sequencing in breast cancer treatment. The evidence supports an earlier integration of CDK4/6 inhibitors combined with aromatase inhibitors for specific resistant tumor profiles, challenging traditional paradigms that reserve such agents for metastatic or late-stage settings. This shift could revolutionize neoadjuvant strategies and help achieve better long-term outcomes.

Beyond breast cancer, the study’s methodological framework provides a scalable template for biomarker-driven trials in other malignancies where endocrine resistance or cell cycle dysregulation play critical roles. The intricate molecular characterization combined with clinical correlation sets a gold standard for trial design, pushing the envelope for precision oncology across cancer types.

In conclusion, the phase 2 trial led by Kong and colleagues marks a pivotal advance, unveiling biomarker signatures of response to palbociclib plus anastrozole in endocrine-resistant ER+/HER2- breast cancer. By bridging molecular science with clinical application, the research not only enhances our understanding of tumor biology but also catalyzes new therapeutic strategies tailored to individual patient profiles. As precision medicine continues its ascent, studies like this pave the way for a future where cancer treatment is as unique as the patients themselves.

This work heralds a new chapter in oncology, where combinatorial neoadjuvant therapies are optimized through biomarker-driven precision, transforming once intractable breast cancers into manageable, and potentially curable, diseases. The profound insight gained from this study will undoubtedly influence research directions, therapeutic guidelines, and ultimately, outcomes for countless patients worldwide.

Subject of Research:
Biomarkers predicting response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer.

Article Title:
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.

Article References:
Kong, T., Mabry, A., Highkin, M. et al. Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nat Commun 17, 949 (2026). https://doi.org/10.1038/s41467-026-68570-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-68570-6

Muscle-invasive bladder cancer represents a critical oncologic entity with a notorious propensity for progression and metastasis. Traditional diagnostic modalities, predominantly imaging and tissue biopsies, present limitations including invasiveness, sampling bias, and inability to capture the temporal heterogeneity of the tumor. The integration of ctDNA analysis circumvents many of these challenges by offering a minimally invasive method to obtain real-time molecular snapshots of tumor genomics through a simple blood draw. This modality holds promise in providing dynamic insights into tumor burden, mutational landscape, and clonal evolution, which are imperative for precision medicine.

The biological foundation of ctDNA stems from apoptotic and necrotic tumor cells releasing fragmented DNA into the bloodstream. This circulating fraction carries tumor-specific genetic alterations such as point mutations, copy number variations, and methylation patterns, which serve as molecular fingerprints. State-of-the-art technologies enable the isolation and high-sensitivity quantification of ctDNA, facilitating an unparalleled window into tumor biology. For MIBC, where early detection of residual disease post-neoadjuvant chemotherapy or surgical resection is critical, ctDNA detection becomes a powerful tool for risk stratification and surveillance.

Translating ctDNA detection into clinical decision-making involves sophisticated genomic profiling and bioinformatic algorithms. By identifying actionable mutations within ctDNA, clinicians can direct therapies that precisely target the evolving tumor subclones. This shift from empirical treatment towards biomarker-driven interventions represents a paradigm change, enhancing therapeutic efficacy while minimizing unnecessary toxicity. Notably, in MIBC, where conventional chemotherapy and radical cystectomy remain standard, ctDNA-guided therapies can identify candidates for emerging targeted therapies or immunotherapy, thereby personalizing care pathways.

One of the paramount challenges in ctDNA applications lies in assay sensitivity and specificity. Given the variable and often low fraction of ctDNA circulating in plasma, particularly in early-stage or minimal residual disease settings, technological advancements such as digital droplet PCR (ddPCR), next-generation sequencing (NGS), and error-corrected sequencing are essential. These methodologies amplify minute quantities of ctDNA while discriminating true tumor-derived alterations from background noise or clonal hematopoiesis. For MIBC, achieving reliable ctDNA detection thresholds is crucial for integrating this biomarker into routine clinical workflows.

Longitudinal monitoring of ctDNA provides a dynamic biomarker for treatment response and early relapse detection. In the context of MIBC, serial ctDNA measurements can reveal molecular residual disease (MRD) status following definitive therapy. Persistent or rising ctDNA levels often precede radiographic evidence of disease recurrence by months, affording a critical window for pre-emptive therapeutic interventions. This temporal sensitivity positions ctDNA as a game-changer in post-treatment surveillance, facilitating timely modifications in treatment strategy based on tumor resurgence activity.

Molecular heterogeneity and clonal evolution constitute central impediments to effective MIBC management. The tumor genome in MIBC evolves under selective pressures imposed by therapy, enabling resistant subclones to emerge. ctDNA profiling captures this evolutionary trajectory, furnishing insights into resistance mechanisms such as mutations in DNA damage repair genes or alterations in immune checkpoint pathways. Understanding these alterations empowers oncologists to anticipate therapeutic resistance and adapt treatments, thereby circumventing relapse and prolonging patient survival.

Integrating ctDNA analysis with other emerging biomarkers and clinical parameters may enhance the precision of personalized therapy. For example, combining ctDNA mutational burden assessments with urinary biomarkers, imaging findings, and patient-specific factors can synergistically delineate high-risk profiles. This multi-dimensional approach fosters a holistic perspective on MIBC tumor biology, enabling the design of individualized treatment regimens that optimize efficacy while preserving quality of life.

The current clinical trials landscape reflects a burgeoning interest in ctDNA-guided therapeutic strategies for MIBC. Recent studies incorporate ctDNA assays as integral components of trial design to evaluate neoadjuvant chemotherapy response, guide adjuvant therapy selection, and monitor immune checkpoint inhibitor efficacy. Early data suggest that ctDNA-positive patients might benefit from intensified therapeutic regimens, while ctDNA-negative individuals may avoid overtreatment. These findings hold profound implications for resource allocation and health economics in oncology practice.

Despite its promise, ctDNA implementation faces barriers including standardization of assays, regulatory approvals, and integration into existing diagnostic pathways. Harmonization of ctDNA analysis protocols and establishment of universally accepted thresholds are essential to ensure reproducibility and comparability across institutions. Moreover, educating clinicians about the interpretation and clinical utility of ctDNA results is pivotal to foster widespread adoption and maximize patient benefit in MIBC care.

Ethical considerations also come to the forefront with ctDNA-driven personalized therapy. The detection of minimal residual disease or preclinical relapse raises challenges regarding patient counseling, psychological impact, and decision-making. Balancing the benefits of early intervention against the risks of overtreatment requires nuanced clinical judgment and patient-centered communication strategies. Future protocols must incorporate frameworks to navigate these complex ethical landscapes in the context of ctDNA-guided MIBC management.

From a technological standpoint, the future of ctDNA analysis may align with advancements such as artificial intelligence and machine learning. These tools can integrate vast datasets from ctDNA sequencing with clinical variables to generate predictive models and treatment algorithms. The fusion of molecular diagnostics with computational analytics promises to accelerate precision oncology, enabling real-time adaptive therapy for MIBC with unprecedented granularity and accuracy.

Particularly intriguing is the potential for ctDNA to uncover novel therapeutic targets in MIBC. Deep sequencing of ctDNA can reveal rare mutations or epigenetic changes not previously identified through tissue biopsy. This expands the therapeutic arsenal, opening avenues for the development of drugs targeting previously unrecognized vulnerabilities within the tumor genome. Consequently, ctDNA research may catalyze a new wave of drug discovery and clinical trial innovations focused on MIBC.

Furthermore, ctDNA may serve a role beyond individualized therapy direction, contributing to population-level cancer control efforts. Screening high-risk populations such as smokers or those with prior bladder cancer history using ctDNA assays could facilitate early MIBC detection, drastically shifting morbidity and mortality patterns. Public health initiatives incorporating liquid biopsy technology could redefine bladder cancer screening paradigms, rendering early-stage diagnosis more accessible and less invasive.

In conclusion, the integration of circulating tumor DNA analysis into the diagnostic and therapeutic continuum for muscle-invasive bladder cancer signifies a watershed moment in oncology. By harnessing the molecular insights afforded by ctDNA, clinicians are now equipped to transition from a one-size-fits-all approach to a highly personalized model of care that dynamically adapts to tumor evolution. While challenges remain, ongoing innovations and clinical validation efforts are rapidly paving the way for ctDNA-guided therapies to become standard practice, promising improved outcomes and individualized hope for patients confronting MIBC.

Subject of Research: Personalized therapy strategies guided by circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer.

Article Title: From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.

Article References:
Suelmann, B.B.M., van der Heijden, M.S. From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01113-y

Image Credits: AI Generated